A5069485392- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Microtubule and mitosis dynamics
- Cancer Immunotherapy and Biomarkers
- Liver physiology and pathology
- Respiratory viral infections research
- Advanced Radiotherapy Techniques
- Bacterial Identification and Susceptibility Testing
- Amoebic Infections and Treatments
- Endoplasmic Reticulum Stress and Disease
- Congenital Anomalies and Fetal Surgery
- Hepatitis B Virus Studies
- Pediatric health and respiratory diseases
- Management of metastatic bone disease
- Cystic Fibrosis Research Advances
- Parasitic infections in humans and animals
- Viral gastroenteritis research and epidemiology
- Oral health in cancer treatment
Hunan Cancer Hospital
2023
Central South University
2023
Qinghai University
2021
China-Japan Friendship Hospital
2019
China Medical University
2017
To assess the safety and efficacy of local ablation plus PD-1 inhibitor toripalimab in previously treated unresectable hepatocellular carcinoma (HCC).In multicenter, two-stage, randomized phase 1/2 trial, patients were randomly assigned to receive alone (240 mg, every 3 weeks), subtotal followed by starting on post-ablation day (Schedule D3), or 14 D14). The first endpoint stage 1 was determine which combination schedule could continue progression-free survival (PFS) as primary for 1/2.A...
<p>Supplementary Method, Table 1-9</p>
<p>Supplementary Fig. 4 A. Progression-free survival by PD-L1 status. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 3 A. Progression-free survival by CD8+ TIL density. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 1 Forest plot of subgroup analysis for progression-free survival (A) and overall (B).</p>
<p>Supplementary Fig. 2 The association of CD8+ TIL density and PD-L1 expression with tumor objective response.</p>
<div>Abstract<p>Purpose: To assess the safety and efficacy of local ablation plus PD-1 inhibitor toripalimab in previously treated unresectable hepatocellular carcinoma (HCC). Patients Methods: In multicenter, two-stage, randomized phase 1/2 trial, patients were randomly assigned to receive alone (240mg, every 3 weeks), subtotal followed by starting on post-ablation day (Schedule D3) or 14 D14). The first endpoint stage 1 was determine which combination schedule could continue...
<p>Supplementary Method, Table 1-9</p>
<p>Supplementary Fig. 1 Forest plot of subgroup analysis for progression-free survival (A) and overall (B).</p>
<p>Supplementary Fig. 2 The association of CD8+ TIL density and PD-L1 expression with tumor objective response.</p>
<p>Supplementary Fig. 3 A. Progression-free survival by CD8+ TIL density. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 4 A. Progression-free survival by PD-L1 status. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 1 Forest plot of subgroup analysis for progression-free survival (A) and overall (B).</p>
<div>AbstractPurpose:<p>To assess the safety and efficacy of local ablation plus PD-1 inhibitor toripalimab in previously treated unresectable hepatocellular carcinoma (HCC).</p>Patients Methods:<p>In multicenter, two-stage, randomized phase 1/2 trial, patients were randomly assigned to receive alone (240 mg, every 3 weeks), subtotal followed by starting on post-ablation day (Schedule D3), or 14 D14). The first endpoint stage 1 was determine which combination schedule...
<p>Supplementary Fig. 4 A. Progression-free survival by PD-L1 status. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 4 A. Progression-free survival by PD-L1 status. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 3 A. Progression-free survival by CD8+ TIL density. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Fig. 2 The association of CD8+ TIL density and PD-L1 expression with tumor objective response.</p>
<p>Supplementary Fig. 1 Forest plot of subgroup analysis for progression-free survival (A) and overall (B).</p>
<p>Supplementary Fig. 2 The association of CD8+ TIL density and PD-L1 expression with tumor objective response.</p>
<p>Supplementary Fig. 3 A. Progression-free survival by CD8+ TIL density. B. Overall Dot marks indicate censored data.</p>
<p>Supplementary Method, Table 1-9</p>
<div>Abstract<p>Purpose: To assess the safety and efficacy of local ablation plus PD-1 inhibitor toripalimab in previously treated unresectable hepatocellular carcinoma (HCC). Patients Methods: In multicenter, two-stage, randomized phase 1/2 trial, patients were randomly assigned to receive alone (240mg, every 3 weeks), subtotal followed by starting on post-ablation day (Schedule D3) or 14 D14). The first endpoint stage 1 was determine which combination schedule could continue...